findings, and presence of autoantibodies. The pathogenesis of autoimmune hepatitis postulates an environmental agent that triggers a cascade of Tcell-mediated events directed at liver antigens in a host genetically predisposed to this disease, leading to a progressive necroinflammatory and fibrotic process and ultimately cirrhosis in the liver. Environmental agents assumed to induce autoimmune hepatitis have not been delineated, but viruses, certain drugs and herbal agents may lead to autoimmune hepatitis.
Certain drugs, including oxyphenisatin, methyldopa, nitrofurantoin, diclofenac, interferon, infliximab, pemoline, minocycline, atorvastatin, and rosuvastatin can induce hepatocellular injury that mimics autoimmune hepatitis (1) (2) (3) (4) (5) . It has also been suggested that herbal agents such as Dai-saiko-to and black cohosh might trigger autoimmune hepatitis (6) . Whether drugs and herbs unmask or induce autoimmune hepatitis or simply cause a drug-induced hepatitis with accompanying autoimmune features is unclear.
We describe the clinicopathologic details of eight cases with ornidazole-induced hepatitis with autoimmune features.
MATERIALS AND METHODS
Patients who presented with acute hepatitis between February 2001 and March 2009 were re-evaluated for the etiology of liver disease. Acute hepatitis was defined as a biochemical abnormality of hepatocellular pattern of damage (alanine aminotransferase [ALT] >3 times the upper limit) within three months after the withdrawal of the drug in patients without a chronic liver disease history (7).
All available data for the tests that were performed at the time of diagnosis, including viral hepatitis markers (antihepatitis A virus (HAV) IgM, hepatitis B surface antigen (HBsAg), anti-hepatitis B core antigen, anti-hepatitis B surface antigen, hepatitis B virus (HBV) DNA by polymerase chain reaction (PCR), anti-hepatitis C virus (HCV), HCV RNA, anti-hepatitis E virus (HEV), anti-cytomegalovirus (CMV) IgM, anti-CMV IgG, monospot test, and Paul Bunnell test), auto-antibodies (antinuclear antibodies (ANA), anti-mitochondrial antibody (AMA), anti-smooth muscle antibody (ASMA) and anti-liver-kidney microsomal (LKM1) antibody) and laboratory investigations to exclude metabolic liver disease (alpha1-antitrypsin, ferritin, ceruloplasmin and serum/urinary copper, detailed history) were retrospectively evaluated.
Patients with acute viral hepatitis, metabolic liver disease, vascular liver disease such as Budd-Chiari syndrome, biliary obstruction, or alcohol consumption were excluded. Doppler ultrasonography and magnetic resonance cholangiopancreatography were used to investigate the biliary system and vascular pathology, if present.
The autoimmune hepatitis scores, which were calculated at the time of diagnosis according to the criteria of the International Autoimmune Hepatitis Group, were recorded (8) . In addition, the simplified criteria of the same group were applied retrospectively to each patient (9) .
Patients with ornidazole-induced toxic hepatitis with autoimmune hepatitis were included to constitute the study group of this report.
When no biochemical and clinical recovery was achieved despite a rather long waiting time (32-90 days) despite the N-acetyl cysteine therapy, liver biopsy was performed in all patients. The second biopsy was done in one of these patients after three years. The available liver biopsies were systematically reviewed with special attention to the presence of interface hepatitis, the composition of the portal infiltrate (predominantly lymphoplasmacytic vs mixed vs lymphocytic infiltrate, presence of eosinophils), rosetting of liver cells, biliary changes, perivenular confluent necrosis and inflammation (peri-venulitis), acute lobular hepatitis with apoptotic bodies, hepatocyte ballooning, Kupffer cell hyperplasia, other histopathological findings, and fibrosis. All biopsies were scored according to the hepatitis scoring system by Ishak et al. (10) .
The treatment charts and follow-up data were recorded for each patient.
RESULTS
Three hundred and ten patients presented with acute hepatitis between February 2001 and March 2009. Toxic hepatitis due to various drugs was diagnosed in 128 patients. Among them, a history of ornidazole treatment was detected in 13 patients; 5 of them recovered spontaneously after the withdrawal of the drug. Table 1 . With the exception of one patient, all were treated with prednisolone 30 mg/day + azathioprine 50 mg/day. The prednisolone dose was tapered according to the decrease in the level of transaminases. Although four patients were diagnosed with diabetes mellitus, a two-year treatment program was planned and performed in all patients because diagnoses in these patients according to liver biopsy were autoimmune hepatitis.
In three patients diagnosed to have diabetes mellitus type 2 at admittance, insulin was started concurrently with prednisolone. Insulin was stopped at the end of one year in all three patients after the tapering of prednisolone. One patient, who was diagnosed as diabetes mellitus type 2 before admittance and who was on metformin 1000 mg/day for about two years, was put on the same insulin treatment scheme as the above-mentioned three patients. We did not consider the possibility of metformin-related acute hepatitis in view of the history of its use for an extended period.
Two patients had previously been diagnosed to have autoimmune (Hashimoto) thyroiditis and one patient had been diagnosed as Sjögren's syndrome.
According to the International Autoimmune Hepatitis Group (8) criteria, patients were classified as: definite autoimmune hepatitis (n=1) or probable autoimmune hepatitis (n=7). The histopathological data of all patients are summarized in Table  2 .
A pattern of liver injury with hepatitic features was observed in all eight patients who had liver biopsy. The appearances were those of interface hepatitis (6/8) licular cholestasis and cholestatic rosettes, and giant cell hepatocytes (Figure 3a) . The second biopsy performed three years later showed features of chronic hepatitis with interface hepatitis and portal fibrosis (Figure 3b ).
The duration of the intake and dose of the drug and the time interval between the diagnosis and treatment were different in each patient; these data are summarized in Table 3 . In all patients, liver biopsy revealed hepatocellular pattern of damage as described in the criteria of the 'International Consensus Meeting for liver injury' (11) . During the time before introducing treatment, transaminase and bilirubin levels were almost unchanged.
Transaminase and bilirubin levels returned to normal levels within 1-6 weeks in all of the 7 patients who were treated with prednisolone 30 mg/day + azathioprine 50 mg/day. In one patient, treatment was discontinued after the two-year treatment protocol was completed, and clinical and biochemical remission was sustained. The other six patients are still under immunosuppressive therapy, and remission is ongoing in all six patients. The first patient in this series (Case 1) did not receive any immunosuppressive treatment and underwent liver transplantation. This patient had a history of ornidazole intake three times with six-and eight-month intervals and developed three attacks of acute hepatitis, during which auto-antibodies were found to be negative. ALT level was consistently found to be >100 IU/L after the Table 2 . Liver biopsy findings F Fi ig gu ur re e 2 2. . Perivenular confluent necrosis and inflammation (peri-venulitis) with predominantly plasma cells (Hematoxylin-eosin, x400).
last intake of the drug. Decompensated cirrhosis developed after six years, and ANA was found to be positive (1/160) at the time of decompensation. The details of this case were previously reported (12).
Bilirubin levels, transaminases and prothrombin time returned to normal limits after 50 days of prednisolone + azathioprine treatment. Outcomes of the patients are summarized in Table 4 .
DISCUSSION
In this article, we present eight patients with ornidazole-induced autoimmune hepatitis, among whom seven were successfully treated with immunosuppressive therapy. When the patients were scored according to the criteria of the International Autoimmune Hepatitis Group (8), one patient was diagnosed as definite autoimmune hepatitis (score=18) and 7 patients as probable autoimmune hepatitis (scores=12-17). However, because of the low sensitivity and specificity of these criteria, the same group reported new simplified criteria in 2008 (9) . A retrospective analysis of the patients according to these simplified criteria revealed that six patients were diagnosed as definite autoimmune hepatitis and 2 patients as probable autoimmune hepatitis. This small study corroborates that the new simplified criteria may be even more valuable since immunosuppressive therapy (prednisolone + azathioprine) was successful in all cases.
Despite the absence of immunosuppressive therapy, a complete clinical, histopathological and biochemical recovery after the drug withdrawal may be achieved in patients with drug-induced autoimmune hepatitis. Thus, the necessity of immunosuppressive therapy for the present patients is a question. However, no biochemical recovery was achieved despite a rather long waiting time (32-90 According to current findings, we may speculate that "simple" drug-induced hepatotoxicity may resolve spontaneously if the immune system is not triggered; however, in cases with immune activation, immunosuppressive therapy is necessary. To differentiate those two scenarios, liver biopsy may help. In this case series, all the drug-induced autoimmune hepatitis developed after the use of ornidazole. This drug is a well-known hepatotoxic drug. Ornidazole is also well-known to cause either hepatocellular or cholestatic pattern of liver damage (13, 14) . Ornidazole-induced autoimmune hepatitis was also reported in one patient previously (15) . Unlike these studies, we used immunosuppressive therapy because we had a negative experience that was previously reported (12) . One can speculate that many patients with ornidazoleinduced autoimmune hepatitis might not be reported in the English literature.
In conclusion, ornidazole may cause drug-induced autoimmune hepatitis. Withdrawal of the drug may not provide the recovery despite a rather long wait. Thus, immunosuppressive therapy may be suggested in these cases. Table 4 . Score results and outcomes of the patients
